COVID-19 care recommendations for people using home-based ventilation

Le français suit

 

As COVID-19 continues to affect our daily lives, it is critical that we try to limit the spread of the virus as much as possible. This is especially applicable for patients who use non-invasive positive-pressure ventilation (NIPPV), mechanical airway clearance devices, or are supported by home ventilation for other chronic respiratory failure syndromes.

Chronic respiratory failure conditions include:

  • Amyotrophic lateral sclerosis (ALS)
  • Chronic obstructive pulmonary disease (COPD)
  • Complicated pneumonia
  • Cystic fibrosis
  • Duchenne muscular dystrophy
  • Myotonic dystrophy
  • Severe obesity hypoventilation syndrome
  • Spinal cord injuries
  • Spinal muscular atrophy
  • Thoracic cage disorders

NIPPV devices can increase the risk of infectious particles being dispersed into the environment, which can then infect the people around you. This risk is especially concerning with poor fitting mask interfaces, high leak, and open ventilation systems with tracheostomy.

To help limit the spread of these particles, the CHEST Foundation has provided recommendations and guidelines to help keep you and your loved ones stay as healthy as possible, which can be downloaded HERE.

***

 

 

 

 

Comme la COVID-19 continue d’affecter notre vie quotidienne, il est essentiel que nous essayions de limiter la propagation du virus autant que possible. Cela s’applique en particulier aux patients qui utilisent la ventilation non invasive (VNI) à pression positive, les dispositifs mécaniques de dégagement des voies respiratoires, ou qui sont soutenus par une ventilation à domicile pour d’autres syndromes d’insuffisance respiratoire chronique.

Les affections liées à l’insuffisance respiratoire chronique comprennent :

  • La sclérose latérale amyotrophique (SLA)
  • Maladie pulmonaire obstructive chronique (MPOC)
  • Pneumonie compliquée
  • Fibrose kystique
  • La dystrophie musculaire de Duchenne
  • La dystrophie myotonique
  • Syndrome d’hypoventilation de l’obésité sévère
  • Lésions de la moelle épinière
  • Atrophie musculaire de la colonne vertébrale
  • Troubles de la cage thoracique

Les VNI à pression positive peuvent augmenter le risque de dispersion de particules infectieuses dans l’environnement, qui peuvent ensuite infecter les personnes autour de vous. Ce risque est particulièrement préoccupant pour les interfaces de masque mal ajustées, les fuites importantes et les systèmes de ventilation ouverts avec trachéotomie.

Pour aider à limiter la propagation de ces particules, CHEST Foundation ont fourni des recommandations et des lignes directrices pour aider vous et vos proches à rester en bonne santé autant que possible, qui vous pouvez télécharger ICI.

 

 

 

virus

Read next...

AGAMREE (vamorolone) Approved treatment for DMD in Canada

A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada

Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.

Website - SBMA published on CMAJ.png

New Best Practice Recommendations for SBMA Care in Canada

Congratulations to Dr. Kerri Schellenberg, the team of Canadian experts, NMD4C Steering Committee members and Investigators, on publishing the first Canadian SBMA care guidelines!

2025 NMD4C ANNUAL MEETING

Advancing Neuromuscular Research and Care: Highlights from the 2025 NMD4C Annual Meeting

On September 11, NMD4C hosted its 2025 Annual Meeting in Ottawa, bringing together clinicians, researchers, trainees, and partners for a full day of collaboration, strategic dialogue, and community-building.

2025 Clinical Summer School

NMD4C Hosts Inaugural Clinical Summer School to Empower Canada’s Future Neuromuscular Leaders

On September 10–11, NMD4C hosted its inaugural Clinical Summer School in Ottawa, bringing together 19 neuromuscular clinical fellows from across Canada for two days of hands-on training, mentorship, and networking. Led by national experts and co-chaired by Drs. Gordon Jewitt and Marianne Nury, the program complemented NMD4C’s accredited lecture series and fostered peer connection through dedicated community-building sessions.

2026 Neuromuscular Postdoc Research Fellowship Competition

2026 Neuromuscular Postdoctoral Research Fellowships Funding Competition is Now Open!

Apply Or Share this opportunity with the trainees in your network — Deadline: October 14, 2025. Hosted by Neuromuscular Disease Network for Canada (NMD4C) and Muscular Dystrophy Canada (MDC)

Clinical Fellowship Awardees

Announcing the 2026 Neuromuscular Clinical Fellowship Award Recipients

We are excited to share that the 2026 Neuromuscular Clinical Fellowship Awards have been awarded! These fellowships strengthen clinical training in neuromuscular medicine and help prepare the next generation of specialists who will advance neuromuscular care across Canada.